港股详情

本页面由Tiger Trade Technology Pte. Ltd.提供服务

抗疫概念

880.948

-3.169-0.36%

涨家数：5

跌家数：12

平家数：- -

市盈率：- -

高：884.415

开：884.196

低：862.733

收：884.117

成交量：1.34亿

成交额：10.36亿

市值：5,960.91亿

流通市值：4,928.38亿

数据加载中...

总览新闻资讯

石药集团启动JMT206注射液Ib期临床试验，评估单药及联合司美格鲁肽治疗肥胖症

石药集团：JMT206注射液用于成人肥胖症治疗的Ib期临床试验在中国首家研究中心启动

石药集团(01093)：JMT206注射液用于超重或肥胖成人患者体重管理的Ib期临床试验在中国首家研究中心正式启动

石药集团(01093)：重组带状疱疹疫苗(SYS 6052)在美国获临床试验批准

迪哲医药：公司收到阿斯利康6亿美元首付款

山东新华制药股份(00719.HK)：刘雪松辞任副总经理

《大行》花旗：中生制药(01177.HK)与STADA达成生物类似药战略合作带来惊喜

阿斯达克财经

中国生物制药就K药生物类似药达成海外授权，国产生物类似药出海再下一城

港股异动 | 礼邦医药-B(09637.HK)午后涨近8% AP308/PKU308获美国FDA临床试验许可

阿里健康(00241)出现大手卖出82.6万股，成交价$2.84，涉资234.584万

阿斯达克财经

君实生物等在嘉兴成立股权投资合伙企业出资额3.6亿

南方财经网

礼邦医药－Ｂ(09637)股价上升5.034%，现价港币$24.62

阿斯达克财经

港股异动 | 劲方医药-B(02595)早盘涨近8% 在研口服新药拟纳入突破性治疗品种

国际医药交易平台累计交易额超6亿元，助力我国药械“出海”

凤凰网财经

港股异动 | 中国生物制药(01177)涨近4% 附属与STADA就生物类似药达成战略合作首付款获最高达5300万欧元

《股市简讯》中国生物制药涨3.2%，将从德国STADA的授权交易中收取首付款

《股市简讯》中国石药集团涨2.6%，mRNA癌症疫苗获批临床试验

普莱医药二闯港交所：现金告急十亿赎回负债悬顶核心产品商业化挑战重重

瞄准创面感染市场拟港股上市企业普莱医药的PL-5值多少钱？

港股开盘偏软恒指高开0.02% 京东健康（06618）涨2.42%

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.etasphere.com/hans/stock/BK1515/news?page=8"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BK1515","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1515\",,,,,undefined,":{"symbol":"BK1515","market":"HK","secType":"PLATE","nameCN":"抗疫概念","latestPrice":880.9478,"timestamp":1791869229035,"preClose":884.1166,"halted":0,"volume":133780124,"delay":0,"changeRate":-0.003584,"floatShares":0,"shares":0,"eps":0,"marketStatus":"交易中","change":-3.168762,"latestTime":"10-13 13:27:13","open":884.1956,"high":884.4146,"low":862.7329,"amount":1036035966,"amplitude":0.024524,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"收盘","tradingStatus":0,"beginTime":1791879000000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"openAndCloseTimeList":[[1791855000000,1791864000000],[1791867600000,1791878400000]],"pbRate":1.340867,"peRate":17.376399,"turnoverRate":0.001833,"increases":5,"decrements":12,"flats":0,"marketCap":596091088640,"floatMarketCap":492837727744},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1515\",,,,,undefined,":{"symbol":"BK1515","high":884.4146,"amplitude":0.024524,"preClose":884.1166,"low":862.7329,"pbRate":"1.340867","latestPrice":880.9478,"volume":133781124,"delay":0,"open":884.1956,"prevYearClose":1190.107,"prevWeekClose":890.643,"prevMonthClose":925.469,"prevQuarterClose":925.469,"fiveDayClose":924.393,"twentyDayClose":888.076,"sixtyDayClose":922.819,"secType":"PLATE","market":"HK","turnoverRate":0.001833,"peRate":17.376399,"marketCap":596091088640,"floatMarketCap":492837727744,"timestamp":1791869237140,"nameCN":"抗疫概念"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK1515\",,,,undefined,":{"bkCode":"BK1515","up":5,"down":12,"flat":0},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK1515\",pageSize:20,pageCount:8,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1121969395","title":"石药集团启动JMT206注射液Ib期临床试验，评估单药及联合司美格鲁肽治疗肥胖症","url":"https://stock-news.laohu8.com/highlight/detail?id=1121969395","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1121969395?lang=zh_cn&edition=fundamental","pubTime":"2026-09-29 18:13","pubTimestamp":1790676828,"startTime":"0","endTime":"0","summary":"石药集团宣布，将开展一项Ib期临床试验，旨在评估JMT206注射液作为单药疗法，或与司美格鲁肽联合使用，在肥胖症治疗中的效果。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1226288170.HKD","LU1152091754.HKD","IE00BZ08YT58.USD","LU1008478684.HKD","LU1328277881.USD","IE00BZ08YR35.GBP","IE0008369823.USD","LU0314109678.HKD","LU1226287875.USD","IE00B543WZ88.USD","BK1191","LU1152091168.USD","LU0072913022.USD","LU0880133367.SGD","KURE","LU1951186391.HKD","LU0140636845.USD","LU0326950275.SGD","SG9999004220.SGD","BK1515","LU0501845795.SGD","LU1813983027.USD","LU1226288253.USD","LU1993786604.SGD","LU1960683339.HKD","01093","IE0008368742.USD","BK1521","IE00B5MMRT66.SGD","IE00B031HY20.USD","LU1807302812.USD","LU2039709279.SGD","LU1226287529.USD","LU0067412154.USD","HK0000165453.HKD","LU0315179316.USD","LU1226287792.SGD","IE00BZ08YS42.EUR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1160275319","title":"石药集团：JMT206注射液用于成人肥胖症治疗的Ib期临床试验在中国首家研究中心启动","url":"https://stock-news.laohu8.com/highlight/detail?id=1160275319","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1160275319?lang=zh_cn&edition=fundamental","pubTime":"2026-09-29 18:08","pubTimestamp":1790676483,"startTime":"0","endTime":"0","summary":"石药集团宣布，JMT206注射液针对成人患者体重管理的Ib期临床试验已在中国境内首家研究中心正式启动。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2039709279.SGD","LU1951186391.HKD","LU0314109678.HKD","LU1226288170.HKD","BK1521","LU1226287529.USD","LU1152091168.USD","IE00B031HY20.USD","01093","IE00BZ08YR35.GBP","LU1226288253.USD","LU0067412154.USD","LU1960683339.HKD","LU1813983027.USD","BK1515","KURE","IE00BZ08YT58.USD","IE00B5MMRT66.SGD","LU0315179316.USD","LU1226287792.SGD","SG9999004220.SGD","LU0072913022.USD","HK0000165453.HKD","IE0008369823.USD","BK1191","IE00BZ08YS42.EUR","LU0140636845.USD","LU1226287875.USD","LU0880133367.SGD","LU1328277881.USD","LU1152091754.HKD","IE00B543WZ88.USD","LU1807302812.USD","LU0501845795.SGD","LU1993786604.SGD","IE0008368742.USD","LU0326950275.SGD","LU1008478684.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671213399","title":"石药集团(01093)：JMT206注射液用于超重或肥胖成人患者体重管理的Ib期临床试验在中国首家研究中心正式启动","url":"https://stock-news.laohu8.com/highlight/detail?id=2671213399","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671213399?lang=zh_cn&edition=fundamental","pubTime":"2026-09-29 18:06","pubTimestamp":1790676369,"startTime":"0","endTime":"0","summary":"智通财经APP讯，石药集团 发布公告，集团开发的JMT206注射液用于超重或肥胖成人患者体重管理的Ib期临床试验，已在中国首家研究中心正式启动。集团已于2025年11月就该产品用于超重或肥胖适应症，获得中华人民共和国国家药品监督管理局签发的《药物临床试验批准通知书》，并于获批后启动了I期临床试验。I期临床试验数据初步验证了该产品在健康参与者中的安全性、药代动力学及药效动力学特征。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1502148.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BMED","IE00B031HY20.USD","LU0067412154.USD","KURE","LU0880133367.SGD","LU1951186391.HKD","LU1807302812.USD","LU2039709279.SGD","IE00BZ08YS42.EUR","BK1191","IBBQ","IE0008369823.USD","IBBJ","LU1008478684.HKD","LU1328277881.USD","IE0008368742.USD","BK1515","LU0326950275.SGD","LU1226287529.USD","LU0072913022.USD","LU1960683339.HKD","SG9999004220.SGD","IE00B543WZ88.USD","LU1152091754.HKD","IE00BZ08YT58.USD","LU1226288170.HKD","LU0314109678.HKD","LU0501845795.SGD","LU0315179316.USD","PSYK","LU1226287792.SGD","LU1226288253.USD","LU1993786604.SGD","MDTX","IE00BZ08YR35.GBP","LU1226287875.USD","IE00B5MMRT66.SGD","LU0140636845.USD","LU1152091168.USD","01093","LU1813983027.USD","BK1521","HK0000165453.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671341213","title":"石药集团(01093)：重组带状疱疹疫苗(SYS 6052)在美国获临床试验批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2671341213","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671341213?lang=zh_cn&edition=fundamental","pubTime":"2026-09-29 18:04","pubTimestamp":1790676297,"startTime":"0","endTime":"0","summary":"智通财经APP讯，石药集团 发布公告，集团开发的预防用生物制品1类新药重组带状疱疹疫苗已获得美国食品药品监督管理局批准，可在美国开展相关临床研究。本次获批的临床适应症为50岁及以上成人，预防带状疱疹及其并发症。此次美国临床试验的获批，是集团在重组蛋白疫苗领域取得的又一重要成果，为包括重组带状疱疹疫苗在内的预防性疫苗产品的全球开发奠定坚实基础。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1502146.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["HK0000165453.HKD","SG9999004220.SGD","KURE","BK1521","LU0501845795.SGD","LU1008478684.HKD","LU1328277881.USD","IBBQ","IE00B031HY20.USD","IE0008368742.USD","BK1191","LU1226288253.USD","LU2039709279.SGD","LU1226287875.USD","IE00BZ08YS42.EUR","LU0880133367.SGD","159646","IE00BZ08YR35.GBP","BMED","IBBJ","LU0315179316.USD","LU1226287529.USD","LU1951186391.HKD","LU0072913022.USD","IE00B5MMRT66.SGD","01093","LU1226287792.SGD","IE00B543WZ88.USD","LU1993786604.SGD","LU0326950275.SGD","LU1960683339.HKD","IE00BZ08YT58.USD","LU0067412154.USD","LU1152091168.USD","LU1152091754.HKD","LU1226288170.HKD","BK1515","LU0140636845.USD","LU1813983027.USD","LU0314109678.HKD","LU1807302812.USD","PSYK","MDTX","IE0008369823.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671815218","title":"迪哲医药：公司收到阿斯利康6亿美元首付款","url":"https://stock-news.laohu8.com/highlight/detail?id=2671815218","media":"同花顺","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671815218?lang=zh_cn&edition=fundamental","pubTime":"2026-09-29 17:32","pubTimestamp":1790674320,"startTime":"0","endTime":"0","summary":"每经AI快讯，9月29日，迪哲医药公告，公司于2026年7月14日与阿斯利康签署《许可协议》，授予阿斯利康在全球范围内独家开发、商业化舒沃哲的权利，协议于2026年8月31日正式生效。近期公司已 ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tonghuashun_highlight","url":"http://news.10jqka.com.cn/20260929/c680370883.shtml","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://news.10jqka.com.cn/20260929/c680370883.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tonghuashun_highlight","symbols":["159938","BK1515","09939","BK1161","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671629736","title":"山东新华制药股份(00719.HK)：刘雪松辞任副总经理","url":"https://stock-news.laohu8.com/highlight/detail?id=2671629736","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671629736?lang=zh_cn&edition=fundamental","pubTime":"2026-09-29 16:53","pubTimestamp":1790672016,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["00719","BK1515","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671292381","title":"《大行》花旗：中生制药(01177.HK)与STADA达成生物类似药战略合作带来惊喜","url":"https://stock-news.laohu8.com/highlight/detail?id=2671292381","media":"阿斯达克财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671292381?lang=zh_cn&edition=fundamental","pubTime":"2026-09-29 16:11","pubTimestamp":1790669460,"startTime":"0","endTime":"0","summary":"花旗发表研究报告指，中生制药旗下正大天晴与德国药企STADA就生物类似药达成战略合作，授予STADA在欧盟、瑞士、英国及独立国家联合体商业化帕博利珠单抗生物类似药的独家许可，并可选择拓展至美国及海湾合作委员会成员国市场。花旗认为合作带来惊喜。中生制药透露年内对外授权交易合计首付款及近期里程碑付款达3.55亿美元，潜在总交易金额达34亿美元。花旗维持中生制药“买入”评级，目标价10.8元。","market":"fut","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20220712104954076_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20220712104954076_s.jpg"],"rights":{"source":"aastocks_highlight","url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1546966/latest-news/AAFN","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1546966/latest-news/AAFN","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["BK1589","BK1515","01477","BK1521","BK1574","IE00BZ08YS42.EUR","IE00BZ08YT58.USD","HK0000165453.HKD","IE00BZ08YR35.GBP","01177","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671529451","title":"中国生物制药就K药生物类似药达成海外授权，国产生物类似药出海再下一城","url":"https://stock-news.laohu8.com/highlight/detail?id=2671529451","media":"北京商报","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671529451?lang=zh_cn&edition=fundamental","pubTime":"2026-09-29 15:50","pubTimestamp":1790668212,"startTime":"0","endTime":"0","summary":"产品还未进入临床便火速敲定了合作。9月28日晚间，中国生物制药发布公告称，公司附属公司正大天晴药业集团股份有限公司与STADAArzneimittelAG已就生物类似药达成战略合作，授予后者在欧盟、瑞士、英国及独立国家联合体商业化帕博利珠单抗生物类似药TQB3570的独家许可。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202609293886461514.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202609293886461514.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["01177","BK1515","IE00BZ08YR35.GBP","BK1589","IE00BZ08YT58.USD","BK1521","IE00BZ08YS42.EUR","SBHMY","BK1191","HK0000165453.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671296172","title":"港股异动 | 礼邦医药-B(09637.HK)午后涨近8% AP308/PKU308获美国FDA临床试验许可","url":"https://stock-news.laohu8.com/highlight/detail?id=2671296172","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671296172?lang=zh_cn&edition=fundamental","pubTime":"2026-09-29 14:40","pubTimestamp":1790664029,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["09939","09637","BK1515","BK1191","BK1574","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671092298","title":"阿里健康(00241)出现大手卖出82.6万股，成交价$2.84，涉资234.584万","url":"https://stock-news.laohu8.com/highlight/detail?id=2671092298","media":"阿斯达克财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671092298?lang=zh_cn&edition=fundamental","pubTime":"2026-09-29 13:04","pubTimestamp":1790658240,"startTime":"0","endTime":"0","summary":"[大手成交]阿里健康(00241)在下午01:04出现大手卖出，成交量为82.6万，成交价为港币$2.84，涉资234.584万。至目前为止，股价升0.176%，今日最高价为$2.895，而最低价为$2.83，总成交量为3.239千万股，总成交金额港币$9.288千万。","market":"fut","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20180205145550051_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20180205145550051_s.jpg"],"rights":{"source":"aastocks_highlight","url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAV2609294962/aamm-all-category","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAV2609294962/aamm-all-category","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["BK1584","BK1189","00241","BK1515","BK1610","BK1589","BK1501","BK1591","BK1502","BK1571","BK1617","BK1615","BK1247","HK0000165453.HKD","BK1142"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671985492","title":"君实生物等在嘉兴成立股权投资合伙企业 出资额3.6亿","url":"https://stock-news.laohu8.com/highlight/detail?id=2671985492","media":"南方财经网","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671985492?lang=zh_cn&edition=fundamental","pubTime":"2026-09-29 12:27","pubTimestamp":1790656020,"startTime":"0","endTime":"0","summary":"南方财经9月29日电，天眼查App显示，近日，嘉兴源禾创孚股权投资合伙企业（有限合伙）成立，执行事务合伙人为君实创业投资（海南）有限公司，出资额3.6亿元，经营范围为以私募基金从事股权投资、投资管理、资产管理等活动，创业投资。合伙人信息显示，该合伙企业由海盐县国有资本投资运营有限公司、上海君实生物医药科技股份有限公司、海盐嘉睿战新股权投资合伙企业（有限合伙）等共同出资。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202609293886340585.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202609293886340585.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1161","BK1515","01877","BK1583"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671680260","title":"礼邦医药－Ｂ(09637)股价上升5.034%，现价港币$24.62","url":"https://stock-news.laohu8.com/highlight/detail?id=2671680260","media":"阿斯达克财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671680260?lang=zh_cn&edition=fundamental","pubTime":"2026-09-29 11:45","pubTimestamp":1790653500,"startTime":"0","endTime":"0","summary":"[上升股]礼邦医药－Ｂ(09637) 股价在上午11:45比前收市价上升5.034%，现股价为港币$24.62。至目前为止，今日最高价为$24.62，而最低价为$23.54。总成交量为25.52万股，总成交金额为港币$611.442万。","market":"other","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20190515141040914_s.png","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20190515141040914_s.png"],"rights":{"source":"aastocks_highlight","url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAR2609291329/aamm-all-category","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAR2609291329/aamm-all-category","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["BK1574","BK1161","09637","BK1515","BK1191","09939","159938"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671267109","title":"港股异动 | 劲方医药-B(02595)早盘涨近8% 在研口服新药拟纳入突破性治疗品种","url":"https://stock-news.laohu8.com/highlight/detail?id=2671267109","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671267109?lang=zh_cn&edition=fundamental","pubTime":"2026-09-29 11:24","pubTimestamp":1790652253,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，劲方医药-B早盘涨近8%。截至发稿，涨5.47%，报28.9港元，成交额3778.62万港元。消息面上，劲方医药自主研发的口服KRAS G12D抑制剂GFH375用于KRAS G12D突变结直肠癌的适应症被CDE拟纳入突破性治疗品种公示。若通过公示期，这将是GFH375第三次获得突破性疗法认定，此前两次分别针对KRAS G12D突变的非小细胞肺癌和胰腺癌。值得注意的是，劲方医药将于10月15日举行线上投资者交流会，公布GFH375联合西妥昔单抗治疗KRAS G12D突变实体瘤的初步研究数据。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1501911.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1515","BK4588","VXUS","BK1161","BK1574","BK4585","09939","KCAI","159938","02595"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671299187","title":"国际医药交易平台累计交易额超6亿元，助力我国药械“出海”","url":"https://stock-news.laohu8.com/highlight/detail?id=2671299187","media":"凤凰网财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671299187?lang=zh_cn&edition=fundamental","pubTime":"2026-09-29 10:58","pubTimestamp":1790650713,"startTime":"0","endTime":"0","summary":"凤凰网财经讯 据经济参考报报道，国家医保局指导搭建的四个国际医药交易 平台累计交易额已超6亿元人民币，正助力我国药械产品“出海”。国家医保局副局长施子海在9月22日举行的发布会上表示，自去年1月开始，国家医保局已搭建四个国际医药交易（集采）平台，面向东南亚、中亚、中东欧、阿拉伯等地区国家，支持中国药械“走出去”。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.ifeng.com/c/8wob0MycyOj","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"fenghuang_stock","symbols":["BK1574","09939","159938","BK1515","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671264188","title":"港股异动 | 中国生物制药(01177)涨近4% 附属与STADA就生物类似药达成战略合作 首付款获最高达5300万欧元","url":"https://stock-news.laohu8.com/highlight/detail?id=2671264188","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671264188?lang=zh_cn&edition=fundamental","pubTime":"2026-09-29 09:58","pubTimestamp":1790647094,"startTime":"0","endTime":"0","summary":"消息面上，中国生物制药发布公告，集团附属公司正大天晴药业集团股份有限公司与STADA Arzneimittel AG已就生物类似药达成战略合作，双方将携手提升生物类似药在全球多个地区的患者可及性。根据协议的条款及条件，正大天晴将获得首付款，并有权获得潜在开发、监管及销售里程碑付款，合计最高可达5300万欧元。STADA将持有该等生物类似药在授权区域内的上市许可，并享有独家销售及营销权。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1501868.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["IE00BZ08YS42.EUR","EUO","LU2322448957.HKD","MEURmain","LU2272731600.USD","XPH","LU1992135399.USD","BK1589","NBIE","BK1515","KCAI","01177","IE00B5TLWC47.USD","BK1191","LU1992135472.HKD","IBB","HK0000165453.HKD","LU2272731782.SGD","LU2473716301.USD","VXUS","LU2322448791.USD","BK4588","IE00BZ08YT58.USD","BK4585","BK1521","PPH","EURmain","FXE","LU2272731865.HKD","IE00BZ08YR35.GBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671378264","title":"《股市简讯》中国生物制药涨3.2%，将从德国STADA的授权交易中收取首付款","url":"https://stock-news.laohu8.com/highlight/detail?id=2671378264","media":"路透中文","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671378264?lang=zh_cn&edition=fundamental","pubTime":"2026-09-29 09:52","pubTimestamp":1790646762,"startTime":"0","endTime":"0","summary":"《股市简讯》中国生物制药涨3.2%，将从德国STADA的授权交易中收取首付款* 泰国富豪谢氏家族旗下制药公司--中国生物制药1177.HK周二早盘高开1.6%，随后涨幅扩大至3.2%。* 该公司上日公告称，附属公司正大天晴将授予德国制药公司STADA在欧盟、瑞士、英国及独立国家联合体商业化帕博利珠单抗生物类似药的独家许可，正大天晴将获得首付款，并有权获得潜在开发、监管及销售里程碑付款，合计最高可达5,300万欧元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260929:nL4S45L04B:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1515","01177","BK1589","IE00BZ08YR35.GBP","BK1191","IE00BZ08YT58.USD","BK1521","HK0000165453.HKD","IE00BZ08YS42.EUR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671852264","title":"《股市简讯》中国石药集团涨2.6%，mRNA癌症疫苗获批临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=2671852264","media":"路透中文","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671852264?lang=zh_cn&edition=fundamental","pubTime":"2026-09-29 09:45","pubTimestamp":1790646322,"startTime":"0","endTime":"0","summary":"《股市简讯》中国石药集团涨2.6%，mRNA癌症疫苗获批临床试验* 中国石药集团1093.HK周二早盘高开1.8%，随后涨幅扩大至2.6%。* 该公司此前公告称，mRNA癌症疫苗SYS 6077注射液已获中国国家药品监督管理局批准签发药物临床试验批准通知书，可在中国开展临床试验。本次获批的临床适应症为晚期恶性肿瘤。* 石药集团今年迄今涨13.6%，同期恒生指数.HSI下滑4.2%。* 恒生综合行业指数 - 医疗保健业.HSCIH盘中一度升1.9%。（完）更多股市简讯请点选CN-CMN-HOT","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260929:nL4S45L045:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BZ08YR35.GBP","LU1226287529.USD","BK1521","KURE","LU1226288253.USD","IE00B543WZ88.USD","BK1191","SG9999004220.SGD","BK1515","LU0315179316.USD","01093","LU0880133367.SGD","LU1226288170.HKD","LU1807302812.USD","LU1226287875.USD","LU1960683339.HKD","LU1226287792.SGD","LU0326950275.SGD","IE0008368742.USD","IE00BZ08YS42.EUR","LU2039709279.SGD","IE00B5MMRT66.SGD","LU0140636845.USD","LU1152091754.HKD","LU0067412154.USD","LU0072913022.USD","IE00B031HY20.USD","IE00BZ08YT58.USD","LU1152091168.USD","LU1951186391.HKD","LU0501845795.SGD","LU0314109678.HKD","LU1008478684.HKD","LU1328277881.USD","LU1993786604.SGD","LU1813983027.USD","IE0008369823.USD","HK0000165453.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671617972","title":"普莱医药二闯港交所：现金告急十亿赎回负债悬顶 核心产品商业化挑战重重","url":"https://stock-news.laohu8.com/highlight/detail?id=2671617972","media":"新浪证券","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671617972?lang=zh_cn&edition=fundamental","pubTime":"2026-09-29 09:38","pubTimestamp":1790645880,"startTime":"0","endTime":"0","summary":"近日，普莱医药第二次向港交所递交主板上市申请，拟以18A章规则登陆资本市场。现金流告急十亿赎回负债悬顶从财务数据看，2024年、2025年及2026年上半年，公司营业收入分别为519.4万元、333.2万元和219.2万元，相关收入均来源于日用护理产品等边缘业务，主营业务尚未形成收入。因此普莱医药必须在不到18个月的时间内完成聆讯、发行与上市，否则将触发股份回购义务。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/observe/2026-09-29/doc-initmzhf7939283.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1574","09939","159938","HEXmain","BK1515","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671026178","title":"瞄准创面感染市场 拟港股上市企业普莱医药的PL-5值多少钱？","url":"https://stock-news.laohu8.com/highlight/detail?id=2671026178","media":"新浪证券","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671026178?lang=zh_cn&edition=fundamental","pubTime":"2026-09-29 09:35","pubTimestamp":1790645700,"startTime":"0","endTime":"0","summary":"近日，普莱医药二度递表港交所，公司核心创新药培来加南喷雾剂已获得国家药品监督管理局上市批准，用于治疗一度及浅二度烧烫伤创面继发性感染，成为全球首款获批上市的加南类抗菌肽药物。由于烧烫伤创面感染为急性单次发病，患者年均治疗约1次，对应年治疗费用约为400元。商业化权益方面，PL-5为普莱医药自主研发的1类创新药，公司已将中国内地独家商业化权益授予正大天晴，自身保留产品生产、供应与质量管控职责。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/observe/2026-09-29/doc-initmzhm9374562.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK4588","BK1574","159938","KCAI","BK4585","VXUS","09939","IPOS","BK1161","BK1515"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671610412","title":"港股开盘偏软 恒指高开0.02% 京东健康（06618）涨2.42%","url":"https://stock-news.laohu8.com/highlight/detail?id=2671610412","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671610412?lang=zh_cn&edition=fundamental","pubTime":"2026-09-29 09:30","pubTimestamp":1790645423,"startTime":"0","endTime":"0","summary":"金吾财讯 | 港股开盘偏软，恒指高开0.02%，国企指数高开0.13%，恒生科技指数低开0.21%。京东健康涨2.42%，信达生物涨1.82%，石药集团涨1.81%，中国生物制药涨1.64%，中国海外发展涨1.55%。于拟议交易完成后，一汽股份将成为本公司第二大股东。该公司A股将于将于9月29日复牌。内地股市昨日下跌，沪综指低开低走，收市下跌1.7%，沪深两市成交额亦有所增加。","market":"sg","thumbnail":"https://static.szfiu.com/news/20210810/NGVhNjVkZTQ2ODU4ZWQyYjc4YjcyMmRkNWUzMjAzNTczNzI1NTIy.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20210810/NGVhNjVkZTQ2ODU4ZWQyYjc4YjcyMmRkNWUzMjAzNTczNzI1NTIy.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1992687","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["86618","LU0594300419.USD","LU0594300179.USD","SG9999001069.SGD","LU2097828631.EUR","IE00BVYPNP33.GBP","IE00BGHQDM52.EUR","IE00BZ08YS42.EUR","07200","LU0164939612.USD","LU2517655291.USD","SG9999002950.SGD","00016","LU0173614495.USD","LU0061477393.USD","IE0008369823.USD","LU2039709279.SGD","09901","BK1190","LU1807302812.USD","BK1521","BK1240","03115","LU1008478684.HKD","LU0140636845.USD","07500","LU0531971595.HKD","BK1596","BK1556","BK1594","03088","09115","LU0164880469.USD","LU0359201612.USD","LU1226287792.SGD","LU2187417386.USD","IE00BSPPW651.USD","LU0605514214.HKD","03417","IE0034224299.USD","LU0329678337.USD","02833","BK1258","LU0082770016.USD","LU1152091168.USD","07226","CAOVY","LU0456827905.SGD","LU1831875114.USD","LU0096374516.USD","LU0052750758.USD","SUHJY","BK1142","LU0359202008.SGD","03033","LU0314109678.HKD","LU1951186391.HKD","03037","BK1592","LU0072913022.USD","02837","00688","LU0708995583.HKD","03419","LU0737861772.HKD","SG9999010052.SGD","IE0008368742.USD","LU0149534421.HKD","LU2088748020.USD","LU2929501877.USD","HSTECH","LU0329678170.USD","LU2097828474.EUR","BK1555","LU0737861699.HKD","BK1583","BK1588","LU0224508324.USD","BOAT","BK1247","IE00BZ08YT58.USD","00316","LU1504937902.USD","09067","SBHMY","IE00B1G9TL16.USD","LU1023057109.AUD","03145","EDU","LU0455707207.USD","LU0320764599.SGD","LU0067412154.USD","LU0051755006.USD","LU0607220059.USD","BK1539","SG9999004311.SGD","LU2213484517.USD","BK1191","01209","LU0502904849.HKD","BK1103","LU1880383366.USD","LU2242644610.SGD","LU0456846285.SGD","LU1163227496.USD","LU1969619763.USD","LU2328871848.SGD","LU0315179316.USD","LU2088748293.HKD","02238","LU2517655028.SGD","SGXZ62798434.SGD","LU0886674414.USD","02635","IE00B543WZ88.USD","LU1481107354.HKD","LU0287142896.SGD","603993","513600","SG9999009997.SGD","HHImain","LU1316543674.SGD","LU2488822045.USD","SG9999004220.SGD","LU1226287875.USD","LU0871576103.HKD","06618","LU0164865239.USD","MCHmain","LU0501845795.SGD","LU1163227579.USD","83115","LU1188198961.HKD","LU1813983027.USD","03121","LU1328277881.USD","LU1993786604.SGD","LU0588546209.SGD","SG9999006597.SGD","LU0082770016.SGD","SG9999010078.USD","LU0650527681.SGD","01801","07300","BK1591","HSI","LU2517655374.HKD","09088","LU2226123490.SGD","LU1224709979.USD","LU0229494975.USD","LU1539696804.USD","LU0307460666.USD","LU2097828805.USD","LU1226288170.HKD","SG9999002463.SGD","BK1515","07552","SG9999001093.SGD","LU1960683339.HKD","OROVY","03993","BK1228","KURE","LU0463099449.HKD","LU2088747725.USD","LU2097828557.USD","02800","01093","LU1226287529.USD","LU2226123227.USD","LU0880133367.SGD","LU0039217434.USD","LU2351347302.SGD","SEA","LU0620787316.HKD","BK1119","IE00BZ08YR35.GBP","LU2088747998.USD","LU0205439572.USD","SG9999001051.SGD","LU1226288253.USD","SGXZ86797644.SGD","82800","01177","HK0000165453.HKD","03032","LU1880383440.USD","03423","80016","BK1542","BK1179","BK1216","BK1601","BK1559","LU0359201885.HKD","LU1152091754.HKD","BK1519","LU0244354667.USD","IE00B1G9TM23.USD","IE00BVYPNQ40.USD","BK1229","IE00B031HY20.USD","BK1589","IE00B5MMRT66.SGD","601238","BK1615","LU0149721374.USD","03067","BK1161","BK1571","LU0326950275.SGD","LU1560770973.SGD","LU2088748376.SGD","LU2097828714.EUR"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":9,"pageCount":8,"totalSize":175,"code":"91000000","status":"200"}]}}